Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult aged 18-55 years.~* Normal medical history and physical examination.~* Normal urine dipstick, blood count, liver enzymes, and creatinine.~Exclusion Criteria:~* Exposure to TB at any point. Previous residence in a TB endemic area.~* Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric disorder, drug or alcohol abuse.~* Oral or systemic steroid medication or the use of immunosuppressive agents.~* Positive HIV antibody test, HCV antibody test or positive HBV serology except post-vaccination.~* Heaf test greater than Grade II~* Confirmed pregnancy~* Previous MVA immunisations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).